Dr. Eric T. Shinohara, MD

Dr. Shinohara practices at Vanderbilt-Ingram Cancer Center at Tennova Healthcare-Clarksville in Nashville, Tennessee.

Dr. Shinohara's NPI, 1780740571, was assigned on December 28, 2006. Dr. Shinohara graduated from Vanderbilt University School of Medicine in 2003. Dr. Shinohara holds Tennessee license MD46126.

Dr. Shinohara's primary practice is Vanderbilt-Ingram Cancer Center at Tennova Healthcare-Clarksville, at 1300 22nd S Ave, Nashville, TN 37212 in Davidson County. The practice phone is (931) 221-0479.

Dr. Shinohara's primary practice is Vanderbilt-Ingram Cancer Center at Tennova Healthcare-Clarksville in Nashville, Tennessee. Dr. Shinohara is also affiliated with Vanderbilt University Medical Center. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Shinohara to 1 more hospital, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shinohara practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Shinohara's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Shinohara's licenses on file in 2 states: Tennessee and Pennsylvania.

CMS data shows 374 Medicare services from Dr. Shinohara across 8 procedure codes in 2024, for 180 Medicare patients. Medicare paid $31,527 for them.

CMS counts 180 Medicare patients who saw Dr. Shinohara in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Shinohara's median patient age at 70, with 30% women.

In 2024, Dr. Shinohara wrote 41 Medicare Part D claims for 15 patients. CMS names the drug for 22 of them, across 1 drug with 11 or more claims each, at $58,086 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

Dr. Shinohara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shinohara as offering telehealth.

Dmand AI links 34 papers to Dr. Shinohara, published from 2011 to 2023. 2014 was the busiest year, with 4. The most frequent topics are SEER Program, Radiotherapy, Adjuvant and Brain Neoplasms. Dr. Shinohara has published most often in Am J Clin Oncol. Dr. Shinohara's most frequent co-authors are James M. Metz, MD, Herbert S. Schwartz, MD and Haydar A. Frangoul, MD.

Dmand AI links Dr. Shinohara to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 3 general payments to Dr. Shinohara from 3 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Augmenix, Inc. paid the most, $145.

Dr. Shinohara graduated from Vanderbilt University School of Medicine in 2003.